Oryzon Genomics – executive interview

Oryzon Genomics is a Spanish biotechnology company focused on epigenetics. Its two lead assets, vafidemstat (central nervous system, CNS) and iadademstat (oncology), are in the clinical stages of development for various indications. Both are small molecule inhibitors of LSD1, a histone-modifying enzyme that forms part of complexes responsible for the regulation of genes implicated in CNS disorders and cancer.

In this video, we catch up with CEO Carlos Buesa for a focused discussion on Oryzon’s CNS pipeline, particularly borderline personality disorder (BPD), a psychiatric condition with no approved treatments and where Oryzon has, to our knowledge, the most advanced clinical programme. Carlos provides an overview of the current landscape for BPD and summarises the clinical data supporting vafidemstat as a promising candidate to address the condition. Notably, in the prior Phase IIb trial, vafidemstat was favoured over placebo in all efficacy measures and the key secondary endpoints were met with statistical significance, showing clinically meaningful benefits. Importantly, vafidemstat was found to be safe and well-tolerated, consistent with the outcomes of previous clinical studies. In the interview, we also learn about Oryzon’s interactions with the US FDA, endorsing its plans for a subsequent Phase III programme, and finish with an overview of key events that investors should watch out for across the next 12–18 months in the CNS and oncology programmes.